A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer
Open Access
- 1 February 2009
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (2) , 389-394
- https://doi.org/10.1038/mt.2008.240
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the LiverHuman Gene Therapy, 2006
- Oncolytic Herpes Simplex Virus-1 Mutant Expressing Green Fluorescent Protein Can Detect and Treat Peritoneal CancerHuman Gene Therapy, 2004
- Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancerCancer Gene Therapy, 2002
- Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex VirusJournal of Virology, 2001
- Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral TherapyHuman Gene Therapy, 2000
- Selective Infection and Cytolysis of Human Head and Neck Squamous Cell Carcinoma with Sparing of Normal Mucosa by a Cytotoxic Herpes Simplex Virus Type 1 (G207)Human Gene Therapy, 1999
- Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinomaDiseases of the Colon & Rectum, 1991
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)The Journal of Infectious Diseases, 1990
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in RodentsThe Journal of Infectious Diseases, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958